Conclusion
This retrospective cohort analysis advances that CF-specific variability is likely to cause the current tobramycin dosing regimen to be sub-optimal. Rigorous identification of additional factors is needed to account for this variability. The evaluation of regimens through their predictive attainment of PK/PD targets remains the fastest way to evaluate a dosing strategy and its factors. Clinically history of APEs is predictive of clinical outcomes. Further population PK models must be developed in our population to optimize current treatment thus increasing clinical efficacy.
References
1. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, et al. Pulmonary exacerbations in cystic fibrosis. Pediatric pulmonology. 2004;37(5):400-6.
2. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012;40(1):61-6.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345-52.
4. Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015;45(3):670-9.
5. Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-8.
6. Prescott WA, Jr. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Respiratory care. 2014;59(9):1353-9.
7. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric pulmonology. 2013;48(6):525-37.
8. Munzenberger PJ, Commissaris RL, Massoud N, Hsu MC. Variability of tobramycin pharmacokinetics in cystic fibrosis. Pediatr Infect Dis J. 1987;6(8):739-43.
9. Vandenbussche HL, Homnick DN. Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2012;17(1):67-77.
10. Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K. Construct and longitudinal validity of a modified Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J. 1999;13(3):552-9.
11. Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. Journal of pharmacokinetics and biopharmaceutics. 1992;20(1):63-94.
12. Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2019;25(10):1286.e1-.e7.
13. Hara M, Masui K, Eleveld DJ, Struys M, Uchida O. Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia. British journal of anaesthesia. 2017;118(3):415-23.
14. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Critical care (London, England). 2013;17(1):204.
15. Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Critical care (London, England). 2013;17(1):205.
16. Alghanem S, Paterson I, Touw DJ, Thomson AH. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. The Journal of antimicrobial chemotherapy. 2013;68(6):1338-47.
17. Crass RL, Pai MP. Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis. Clinical pharmacokinetics. 2019;58(10):1323-32.
18. Alghanem SS, Touw DJ, Thomson AH. Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. The Journal of antimicrobial chemotherapy. 2019;74(8):2311-7.
19. Hong LT, Liou TG, Deka R, King JB, Stevens V, Young DC. Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Chest. 2018;154(5):1108-14.
20. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, et al. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatric pulmonology. 2011;46(10):987-90.
21. Fischer DR, Namanny H, Zobell JT. Follow-up survey of the utilization of anti-pseudomonal beta-lactam antibiotics at U.S. cystic fibrosis centers. Pediatric pulmonology. 2016;51(7):668-9.
22. Prescott WA, Jr., Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy. 2010;30(1):95-108.
23. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis–the TOPIC study: a randomised controlled trial. Lancet (London, England). 2005;365(9459):573-8.
24. Francis J. Gilchrist KJC, A. Kevin Webb, Rowland J. Bright-Thomas, Andrew M. Jones. Possible compromises for the dosing of IV tobramycin in cystic fibrosis. The Pharmaceutical Journal. 2013;290:89.
25. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother. 1987;31(4):594-9.
26. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci. 1998;20(4):149-60.
27. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy. 1991;9(1-2):169-210.
28. Savant AP, McColley SA. Cystic fibrosis year in review 2018, part 1. Pediatric pulmonology. 2019;54(8):1117-28.
29. Savant AP, McColley SA. Cystic fibrosis year in review 2018, part 2. Pediatric pulmonology. 2019;54(8):1129-40.
30. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest. 2005;128(4):2336-46.
31. Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, Borneff-Lipp M, et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2009;15(5):454-60.
32. CFC. The Canadian Cystic Fibrosis Registry: 2017 Annual Data Report. 2017.
33. Rutter WC, Burgess DR, Burgess DS. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates. Microb Drug Resist. 2017;23(1):51-5.
34. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatric pulmonology. 2011;46(4):393-400.
35. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64-72.
36. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. The Cochrane database of systematic reviews. 2003(3):Cd001912.
37. Smyth AR, Rosenfeld M. Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews. 2017(4).
38. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. The Journal of antimicrobial chemotherapy. 2001;47(2):129-40.